Atherion Bioresearch

Atherion Bioresearch

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Atherion Bioresearch is a US-based clinical research organization established by industry veterans to address perceived gaps in traditional CRO partnerships. The company leverages its team's extensive sponsor-side experience, particularly in radiopharmaceuticals and complex therapeutic areas, to serve as a true development partner for biotech and pharmaceutical clients. Its core mission centers on integrity, innovation, and collaboration to advance life-changing therapies efficiently from early development through late-stage trials.

OncologyNeurologyRheumatoid ArthritisCardiology

Technology Platform

Atherion does not own a proprietary technology platform. Its core offering is deep domain expertise and specialized service capabilities in clinical development, operations, and regulatory affairs, with a particular focus on radiopharmaceuticals, radiotherapeutics, and innovative trial design.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Significant growth opportunity exists in the rapidly expanding radiopharmaceutical and radiotherapeutics market, where Big Pharma investment is surging.
The proliferation of virtual and small biotech companies lacking full internal development teams creates sustained demand for expert CRO partners.
Additionally, the increasing complexity of clinical trial design and global regulation favors specialized service providers with deep therapeutic and technical expertise.

Risk Factors

Key risks include intense competition from large, well-resourced global CROs and other boutique firms, potential reliance on a small number of key clients leading to revenue concentration, and the challenge of attracting and retaining specialized talent in a competitive market.
The business is also subject to cyclicality based on biotech funding environments.

Competitive Landscape

Atherion competes against large global CROs (e.g., IQVIA, ICON) and other specialty CROs. Its main differentiation is deep, sponsor-side expertise in the complex niche of radiopharmaceuticals and radiotherapeutics, a collaborative partner-led model, and a leadership team with proven track records in advancing compounds themselves. It positions itself as an agile, expert alternative to larger, less specialized providers.